Who are Meningococcal A (control)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Control 23-valent PPV, polyvalent pneumococcal vaccine, Typhoid Vi vaccine, Investigational 23-valent PPV, Pneumovax™23, PPV Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/meningococcal-a-control.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Meningococcal A (control) — Competitive Intelligence Brief

Meningococcal A (control) (Meningococcal A (control)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: polysaccharide vaccine. Area: Immunology / Infectious Disease.

marketed polysaccharide vaccine Neisseria meningitidis serogroup A capsular polysaccharide Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Meningococcal A (control) (Meningococcal A (control)) — International Vaccine Institute. This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A polysaccharide capsule.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Meningococcal A (control) TARGET	Meningococcal A (control)	International Vaccine Institute	marketed	polysaccharide vaccine	Neisseria meningitidis serogroup A capsular polysaccharide
Control 23-valent PPV	Control 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
polyvalent pneumococcal vaccine	polyvalent pneumococcal vaccine	Astellas Pharma Inc	marketed	Polysaccharide vaccine
Typhoid Vi vaccine	Typhoid Vi vaccine	International Vaccine Institute	marketed	polysaccharide vaccine	Salmonella typhi Vi polysaccharide capsular antigen
Investigational 23-valent PPV	Investigational 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
Pneumovax™23	Pneumovax™23	Merck Sharp & Dohme LLC	marketed	Polysaccharide vaccine
PPV Vaccine	PPV Vaccine	Fakultas Kedokteran Universitas Indonesia	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (polysaccharide vaccine class)

International Vaccine Institute · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Meningococcal A (control) — Competitive Intelligence Brief. https://druglandscape.com/ci/meningococcal-a-control. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab